CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 16 enrolled
Drug / intervention
Ghrelin +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01898611
NCT01898611Phase 2Completed
CompareCT.gov

Ghrelin Plus Strength Training in Frail Elderly Study

University of Pennsylvania·interventional·Posted Jul 12, 2013·Updated Dec 11, 2019

In Brief

A Phase 2 clinical trial evaluating Ghrelin and Placebo for Frailty Syndrome. Completed, enrolled 16 participants across 1 site.

Detailed Summary

Frailty is a geriatric syndrome leading to physical deterioration including muscle wasting (sarcopenia) and unintentional weight loss. There are currently no approved therapies for frailty. Ghrelin is a hormone produced by the stomach that stimulates appetite centers in the brain. The investigators already know that a single dose of Ghrelin improves food intake immediately after the dose in frail older people. In addition, exercise programs have been shown to improve strength and function in older people. In this study, the investigators are trying to find out if a joint intervention of ghrelin and resistance training will improve walking, balance and leg strength in frail elderly people.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsFrailty Syndrome
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedJul 12, 2013
Enrollment StartJul 1, 2013
Primary CompletionAug 31, 2016
TodayJul 2, 2026
Enrollment to primary: 3.2 yearsPosted 13.0 years ago

Interventions

Ghrelindrug

Ghrelin

Placebodrug

Saline will be used as a placebo